HLC urged Congress to preserve incentives for continued biopharmaceutical innovation while pursuing solutions that improve affordability for beneficiaries. The letter raised concerns about proposals to expand Medicare drug price negotiation and impose additional pricing controls, while supporting efforts to strengthen Medicare Part D market stability, expand access to Low-Income Subsidy benefits, and improve uptake of existing affordability programs.
To Congress
HLC response to Senate Finance Committee Democrats’ RFI on Drug Pricing
- Topics: Access, Competition, Innovation
Related Letters & Comments
HLC drives policy change through strategic letters, comments, and reports that promote private-sector innovation. Focused on priorities like Medicare reform, telehealth, and health equity, HLC engages with lawmakers and agencies to shape a smarter, more responsive healthcare system.
To Congress
HLC response to Senate Finance Committee Democrats’ RFI on Health Coverage
HLC urged Congress to strengthen and modernize existing coverage pathways, strongly supporting restoring and building on the enhanced Affordable Care Act premium tax credits, simplifying enrollment and coverage renewal processes, promoting continuit…
To The Administration
Group letter to DOL on advancing the “Electronic Disclosure by Group Health Plans Under ERISA” proposed rule
Stakeholders representing employers, businesses, and environmental organizations urged the Department of Labor (DOL) to finalize its proposal to permit default electronic delivery (e-delivery) for group health plan communications under the Employee …
To Congress
Group letter urging House leadership to advance H.R. 2332/S.1101, the “SHARE Act”
HLC joined the Interstate Healthcare Collaborative and other healthcare organizations in urging House leadership to advance the bipartisan States Handling Access to Reciprocity for Employment (SHARE) Act (H.R. 2332/S. 1101). The legislation would ad…
